A study of Adavosertib as Treatment for Uterine Serous Carcinoma

Trial Identifier: D601HC00002
Sponsor: AstraZeneca
Collaborator:
Parexel International
NCTID:: NCT04590248
Start Date: November 2020
Primary Completion Date: May 2022
Study Completion Date: February 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Spanish Translation
Spanish (United States) Translation
French (Canadian) Translation
French Translation
Italian Translation

Trial Locations

Country Location
CA Toronto, CA, M5G 2M9
ES A Coruña, ES, 15009
ES Barcelona, ES, 08035
ES Barcelona, ES, 08036
ES Pozuelo de Alarcón, ES, 28223
FR Dijon cedex, FR, 21079
FR Marseille, FR, 13273
FR Nice, FR, 6189
FR Pierre Benite, FR, 69495
FR Saint Herblain, FR, 44805
IT Milan, IT, 20141
IT Napoli, IT, 80131
IT Roma, IT, 00168
US, CA Burbank, CA, US, 91505
US, CA Duarte, CA, US, 91010
US, CA La Jolla, CA, US, 92093
US, CA West Hollywood, CA, US, 90048
US, CO Aurora, CO, US, 80045
US, IA Iowa City, IA, US, 52242
US, LA Covington, LA, US, 70433
US, MN Rochester, MN, US, 55905
US, New York Bronx, New York, US, 10467
US, NJ New Brunswick, NJ, US, 08903
US, NY New York, NY, US, 10065
US, WA Spokane, WA, US, 99202
US, WA Vancouver, WA, US, 98684